EUCTR2013-001067-23-NL进行中（未招募）不适用
PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST) - i-PHORECAST
niversity Medical Centre Groningen0 个研究点开始时间: 2013年11月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •PLN R14del mutation carriers
- •Age =30 and = 65 years
- •New York Heart Association functional class = 1
- •LV ejection fraction =.45 (measured with MRI)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Palpitations necessitating treatment (at the discretion of the attending physician)
- •A diagnosis of DCM (see appendix 1). Note: regional LV wall motions abnormalities are acceptable.
- •A diagnosis of ARVC (according to the task force criteria)
- •Global or regional RV dysfunction and/or structural alterations (according to
- •task force criterion 1).
- •Ventricular premature complexes >1000 during 24hours Holter-monitoring
- •Non-sustained ventricular tachycardia during Holter-monitoring or exercise-testing
- •History of sustained ventricular tachycardia or ventricular fibrillation
- •Hypertension requiring the use of antihypertensive drugs, or when this is
- •anticipated within the coming 3 years
- •Evidence of ischemic heart disease
- •Treatment with cardioactive medication
- •Hyperkaliemia (serum potassium >5.0 mmol/l)
- •Severe renal dysfunction (eGFR <30 ml/min/1.73 m2)
- •Severe hepatic impairment (Child-Pugh class C)
- •Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan on becoming pregnant.
- •Concomitant use of CYP3A4-inhibitors
- •Concomitant use of NSAIDs
- •Concomitant use of potassium highering/sparing-agents
- •Known intolerance or contraindication to aldosterone antagonists
- •Participation in another drug trial in which the last dose of drug was within the past 30 days.
- •Contra-indications for MRI (claustrophobia, metal devices)
- •Subjects unable or unwilling to provide written informed consent
- •Note: presence of late gadolinium enhancement on MRI is not an exclusion criterion
研究者
相似试验
已完成
3 期
PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST)genetische aandoeningen: erfelijke cardiomyopathien (late-onset)Phospholamban related CardiomyopathyPhospolamban heart muscle disorder10028593NL-OMON41504niversitair Medisch Centrum Groningen150
已完成
3 期
PHOspholamban RElated CArdiomyopathy STudy - InterventionPhospholamban R14del Mutation-related CardiomyopathyNCT01857856M.p. van den Berg, MD, PhD, professor in Cardiology84
招募中
不适用
Prospactive study for Cyclophosphamide-induced cardiomyopathyJPRN-UMIN000019543Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine40
招募中
不适用
Study of cardiac parasympathetic dysfunction in Parkinson's disease by using wearable devicesParkinson's syndrome, Parkinson's diseaseJPRN-UMIN000030487agoya University80
终止
2 期
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic CardiomyopathyNon-ischemic CardiomyopathySystolic Heart Failure (NYHA II-III)NCT01935622Virginia Commonwealth University10